Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably.
PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.
Constipation, Impaction, and Bowel Obstruction
Extrahepatic Bile Duct Cancer
Gastrointestinal Stromal Tumor
Nausea and Vomiting
Peritoneal Cavity Cancer
Small Intestine Cancer
Drug: octreotide acetate
|Study Design:||Primary Purpose: Supportive Care|
|Official Title:||Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study|
|Study Start Date:||October 1999|
|Study Completion Date:||October 2002|
|Primary Completion Date:||October 2002 (Final data collection date for primary outcome measure)|
- Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer.
- Characterize the dose and tolerability of octreotide in this patient population.
OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5.
Patients who respond well to study may continue octreotide for palliative effects.
PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004895
|United States, Illinois|
|Robert H. Lurie Comprehensive Cancer Center, Northwestern University|
|Chicago, Illinois, United States, 60611-3013|
|Study Chair:||J. Cameron Muir, MD||Robert H. Lurie Cancer Center|